Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Windlas Biotech IPO is a book built issue of Rs 401.54 crores. The issue comprises of fresh issue of Rs 165.00 crore and offer for sale of 0.51 crore shares.
Windlas Biotech IPO bidding started from August 4, 2021 and ended on August 6, 2021. The allotment for Windlas Biotech IPO was finalized on Wednesday, August 11, 2021. The shares got listed on BSE, NSE on August 16, 2021.
Windlas Biotech IPO price band is set at ₹448 to ₹460 per share. The minimum lot size for an application is 30 Shares. The minimum amount of investment required by retail investors is ₹13,800.
Dam Capital Advisors Ltd (Formerly Idfc Securities Ltd), Iifl Securities Ltd and SBI Capital Markets Limited are the book running lead managers of the Windlas Biotech IPO, while Link Intime India Private Ltd is the registrar for the issue.
Refer to Windlas Biotech IPO RHP for detailed information.
| IPO Date | August 4, 2021 to August 6, 2021 |
| Listing Date | August 16, 2021 |
| Face Value | ₹5 per share |
| Price Band | ₹448 to ₹460 per share |
| Lot Size | 30 Shares |
| Total Issue Size | [.] shares (aggregating up to ₹401.54 Cr) |
| Fresh Issue | [.] shares (aggregating up to ₹165.00 Cr) |
| Offer for Sale | 5,142,067 shares of ₹5 (aggregating up to ₹236.54 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 18,207,419 |
| Share holding post issue | 21,794,375 |
Windlas Biotech IPO offers 6,136,252 shares. 1,723,700 (28.09%) to QIB, 1,323,766 (21.57%) to NII, 3,088,786 (50.34%) to RII. 102,959 RIIs will receive minimum 30 shares and (sNII) and (bNII) will receive minimum 450 shares. (in case of oversubscription)
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | - | NA |
| QIB Shares Offered | 1,723,700 (28.09%) | NA |
| NII (HNI) Shares Offered | 1,323,766 (21.57%) | |
| Retail Shares Offered | 3,088,786 (50.34%) | 102,959 |
| Total Shares Offered | 6,136,252 (100%) |
Windlas Biotech IPO opens on August 4, 2021, and closes on August 6, 2021.
| IPO Open Date | Wednesday, August 4, 2021 |
| IPO Close Date | Friday, August 6, 2021 |
| Basis of Allotment | Wednesday, August 11, 2021 |
| Initiation of Refunds | Thursday, August 12, 2021 |
| Credit of Shares to Demat | Friday, August 13, 2021 |
| Listing Date | Monday, August 16, 2021 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 6, 2021 |
Investors can bid for a minimum of 30 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 30 | ₹13,800 |
| Retail (Max) | 14 | 420 | ₹193,200 |
| Lot Size Calculator | |||
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the company promoters.
| Share Holding Pre Issue | 78% |
| Share Holding Post Issue | 65.16% |
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Competitive strengths
| Particulars | For the year/period ended (₹ in million) | ||||
|---|---|---|---|---|---|
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |||
| Total Assets | 2,961.23 | 3,384.88 | 2,981.80 | ||
| Total Revenue | 4,306.95 | 3,313.39 | 3,115.25 | ||
| Profit After Tax | 155.70 | 162.13 | 638.22 | ||
[Dilip Davda] Despite growth in its top lines, WBL has posted declining trends for bottom lines in order to clear its slate. Based on its financial parameters, the issue is aggressively priced. All recent moves will take about two years to be on a fast forward mode. Thus it is purely a long term bet at the current valuations that discounts all near term positives. Cash surplus investors may consider it with a long term perspective. Read detail review...
The Windlas Biotech IPO is subscribed 22.44 times on August 6, 2021 6:50:00 PM. The public issue subscribed 24.22 times in the retail category, 24.40 times in the QIB category, and 15.73 times in the NII category. Check Day by Day Subscription Details (Live Status)
Application Wise IPO Subscription (Retail): 20.63 times
| Category | Subscription (times) |
|---|---|
| QIB | 24.40 |
| NII | 15.73 |
| Retail | 24.22 |
| Total | 22.44 |
| Listing Date | August 16, 2021 |
| BSE Script Code | 543329 |
| NSE Symbol | WINDLAS |
| ISIN | INE0H5O01029 |
| Final Issue Price | ₹460 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹460.00 |
| ₹439.00 |
| ₹405.00 |
| ₹452.10 |
| ₹406.70 |
| NSE |
|---|
| ₹460.00 |
| ₹437.00 |
| ₹405.00 |
| ₹452.00 |
| ₹407.15 |
Windlas Biotech Limited
40/1, Mohabewala Industrial Area,
Dehradun, 248110
Phone: +91 135 6608000
Email: grievance@windlasbiotech.com
Website: http://www.windlasbiotech.com/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: windlas.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Windlas Biotech IPO is a main-board IPO of [.] equity shares of the face value of ₹5 aggregating up to ₹401.54 Crores. The issue is priced at ₹448 to ₹460 per share. The minimum order quantity is 30 Shares.
The IPO opens on August 4, 2021, and closes on August 6, 2021.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Windlas Biotech IPO using UPI as a payment gateway. Zerodha customers can apply in Windlas Biotech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Windlas Biotech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Windlas Biotech IPO opens on August 4, 2021 and closes on August 6, 2021.
Windlas Biotech IPO lot size is 30 Shares, and the minimum amount required is ₹13,800.
You can apply in Windlas Biotech IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Windlas Biotech IPO will be done on Wednesday, August 11, 2021, and the allotted shares will be credited to your demat account by Friday, August 13, 2021. Check the Windlas Biotech IPO allotment status.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
IPO Guru (4400+ Posts, 5100+ Likes)
Top Contributor (200+ Posts, 200+ Likes)
IPO Mentor (700+ Posts, 700+ Likes)
